Memgen Is A Clinical Stage Biotech Company Developing Viral Immunotherapies To Harness The Power Of The Immune System To Potentially Cure Cancer And To Protect People From Infectious Diseasesthe Company S Pipeline Products All Utilize Its Proprietary Cd40L Transgenemem40Which Has Already Demonstrated The Ability To Elicit Powerfulantigen Specific Immune Responses The Company S Lead Cancer Immunotherapymem 288Was Developed In Collaboration With Moffitt Cancer Centerit Is An Oncolytic Virus Engineered To Selectively Target Cancer Cells And To Supercharge The Immune System Through Expression Of Two Unique And Powerful Immune Modulatorsmem40 And The Powerful Cytokine Interferon Betamem 288 Generates A Strong Systemic Anti Tumor Immune Response Following Intra Tumoral Vaccination In Multiple Tumorsmemgen Is Close To Completing The Monotherapy Part Of A Clinical Trial In Advanced Metastatic Nsclc Memgen S Vaccine Adjuvantmemvaxis Designed To Be Used In Combination With Other Vaccines To Generate A Strongdurable Immune Responsememvax Is A Highly Specific Immune Stimulant That Can Work With Antigens Across A Range Of Delivery Approachesmemgen Has Over 100 000 Doses Of Memvax Ready To Go Into Clinical Trialsand An Active File With The Us Fdamemgen Plans To Soon Begin Clinical Trials Of Memvax In Collaboration With Other Companies Developing Complementary Vaccines
No conferences found for this company.
| Company Name | Memgen Llc |
| Country |
United States
|
| Address | N/A |
| Telephone | N/A |
| N/A |
